The market expects Merck (MRK) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on July 30, 2024, might help the stock move higher if these key numbers are better tha ...

The most recent trading session ended with Merck (MRK) standing at $125.69, reflecting a -0.06% shift from the previouse trading day's closing. This change lagged the S&P 500's daily gain of 1.08%. On the other hand, the Dow registered a gain of 0.32%, and the technology-centric Nasdaq increased by 1.58%.The the stock of pharmaceutical company has fallen by 3.79% in the past month, lagging the Medical sector's gain of 0.31% and the S&P 500's gain of 0.43%.Market participants will be closely following the fi ...

Merck (MRK) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Over the past month, shares of this pharmaceutical company have returned -1.6%, compared to the Zacks S&P 500 composite's +2.1% change. During this period, the Zacks Large Cap Pharmaceuticals industry, which Merck falls in, has gained 2.2%. The key question now is: What could be the stock's future directio ...

Merck’s (MRK) stock has risen 17.5% so far this year, underperforming an increase of 24.2% for the industry, as seen in the chart below. Merck Stock Underperforms Industry Image Source: Zacks Investment ResearchMerck boasts more than six blockbuster drugs in its portfolio, with PD-L1 inhibitor Keytruda approved for several types of cancer and alone accounting for more than 45% of the company’s pharmaceutical sales. The drug has played an instrumental role in driving Merck’s steady revenue growth in the past ...

JHVEPhoto/iStock Editorial via Getty Images Since I last wrote about the pharmaceuticals stock Merck & Co., Inc. (NYSE:MRK) in April, its share price has seen a small decline, after a 20% rise in the first quarter of 2024 (Q1 2024). While the developments for the company have been broadly positive since, there are some emerging risk as well. Here, I assess how the balance of the supporting factors and the potential drags sits and what it means for the price going forward. Keytruda stays the highlight Fi ...

UKRAINE - 2021/06/18: In this photo illustration, Elanco (Elanco Animal Health Incorporated) logo of ... [+] an US pharmaceutical company is seen on a smartphone and a pc screen in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesThe stock price of Elanco (NYSE: ELAN), an animal health products company, saw a 20% fall on Thursday, June 27, after the company announced a delay in expected approval of two drugs. In comparison, ...

Merck (MRK) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has given a positive opinion recommending the approval of its pulmonary arterial hypertension (PAH) drug Winrevair (sotatercept) in Europe. The CHMP recommended Winrevair in combination with other PAH therapies for treating adult patients with PAH (WHO Functional Class II to III) to improve exercise capacity.The decision of the European Commission is expected in the third quarter of 2024. If ...

Merck (MRK) announced that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has unanimously voted to recommend MRK’s newly approved 21-valent pneumococcal conjugate vaccine (PCV) Capvaxive. The FDA approved Capvaxive earlier this month for the prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults. Capvaxive became the first PCV specifically designed for adults to be approved by the FDA.Capvaxive targets serotypes that ...

Merck (MRK) and its partner Daiichi Sankyo announced that the FDA has issued a complete response letter (“CRL”) to the biologics license application (BLA) seeking accelerated approval for patritumab deruxtecan for previously-treated EGFR-mutated non-small cell lung cancer (NSCLC).The BLA seeks approval for patritumab deruxtecan, a specifically engineered potential first-in-class HER3-directed DXd antibody drug conjugate (ADC), to treat adult patients with locally advanced or metastatic EGFR-mutated NSCLC pr ...

Merck (MRK) closed the most recent trading day at $132.96, moving +1.71% from the previous trading session. The stock outperformed the S&P 500, which registered a daily loss of 0.31%. On the other hand, the Dow registered a gain of 0.67%, and the technology-centric Nasdaq decreased by 1.09%.The the stock of pharmaceutical company has risen by 0.95% in the past month, leading the Medical sector's gain of 0.61% and undershooting the S&P 500's gain of 2.73%.Market participants will be closely following the fin ...